CAS: 146362-70-1; 2-[[1-(7-Chloroquinolin-4-yl)-5-(2,6-Dimethoxyphenyl)Pyrazole-3-Carbonyl]Amino]Adamantane-2-Carboxylic Acid
- 英文名称2-[[1-(7-Chloroquinolin-4-yl)-5-(2,6-Dimethoxyphenyl)Pyrazole-3-Carbonyl]Amino]Adamantane-2-Carboxylic Acid
- 中文名称2-[[[1-(7-氯-4-喹啉)-5-(2,6-二甲氧基苯基)-1H-吡唑-3-基]羰基]氨基]-三环[3.3.1.13,7]癸烷-2-羧酸
- IUPAC名称(1r,3r,5r,7r)-2-(1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole-3-carboxamido)adamantane-2-carboxylic acid
- CAS编号146362-70-1
- FDA UNII编号:5JBP4SI96H
- 分子式:C32H31ClN4O5分子量:587.07
- 产品CID: 697116
- 产品分类有机原料 → 羧酸类化合物及衍生物
物理性质
上下游产品
CAS号2040-04-2 2,6-二甲氧基苯乙酮 | CAS号42381-05-5 2-氨基金刚烷-2-甲酸 | CAS号703-23-1 1-(2-羟基-6-甲氧基苯基... | CAS号700-58-3 2-金刚烷酮 | CAS号111697-04-2 2-benzamidoadam...合成工艺路线路线简述
📜1-(2-羟基-6-甲氧基苯基)乙基-1-酮置于2,6-二甲基吡啶,三光气,Sodium Ethanolate,N,N-二异丙基乙胺,Potassium Hydroxide体系中,用 四氢呋喃,甲醇,乙醇,二氯甲烷,水,N,N-二甲基甲酰胺 用作溶剂,化学反应 44.42H,反应生成2-[[[1-(7-氯-4-喹啉)-5-(2,6-二甲氧基苯基)-1H-吡唑-3-基]羰基]氨基]-三环[3.3.1.13,7]癸烷-2-羧酸
参考文献:机器辅助的sr48692流动合成:用于研究神经降压素受体-1的探针
标题:机器辅助的sr48692流动合成:用于研究神经降压素受体-1的探针
摘要:这里,我们报告meclinertant(sr48692,的常规分批方式合成的直接比较1),神经降压素受体-1拮抗剂,以其机器辅助流动化学替代.通过使用这些辅助工具,再加上固体支持的试剂和清除剂,可以观测到许多工艺优势.但是,必须注意不要将这些技术转换为不存在的问题的昂贵解决方案.
Doi:10.1002/chem.201300696
海关参考信息
- 2903919090-氯苯
2905121000-正丙醇
2907221000-对苯二酚
2912110000-甲醛 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:EP-4630405-A1
优先权日:2022-12-06
标题 :Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
专利号:WO-2024123815-A1
优先权日:2022-12-06
标 题:Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
专利号:RU-2195455-C2
优先权日:1995-04-11
标 题 :Substituted 1-phenyl-3-carboxamides and their pharmaceutically acceptable salts, method of their synthesis, intermediate compounds and pharmaceutical composition based on thereof showing affinity to human neurotensin receptors
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Baxendale IR, Cheung S, Kitching MO, Ley SV, Shearman JW. The synthesis of neurotensin antagonist SR 48692 for prostate cancer research. Bioorg Med Chem. 2013 Jul 15;21(14):4378-87. doi: 10.1016/j.bmc.2013.04.075. Epub 2013 May 6. doi: 10.1016/j.npep.2011.01.002. Epub 2011 Jan 26.
8: Herzig MC, Chapman WG, Sheridan A, Rake JB, Woynarowski JM. Neurotensin receptor-mediated inhibition of pancreatic cancer cell growth by the neurotensin antagonist SR 48692. Anticancer Res. 1999 Jan-Feb;19(1A):213-9.
15: Botto JM, Guillemare E, Vincent JP, Mazella J. Effects of SR 48692 on neurotensin-induced calcium-activated chloride currents in the Xenopus oocyte expression system: agonist-like activity on the levocabastine-sensitive neurotensin receptor and absence of antagonist effect on the levocabastine insensitive neurotensin receptor. Neurosci Lett. 1997 Feb 28;223(3):193-6.
合成参考文献
参考文献:10.1016/0006-8993(96)00407-6|10.1016/s0006-8993(96)00407-6
摘要:Chapman MA, See RE. The neurotensin receptor antagonist SR 48692 decreases extracellular striatal GABA in rats. Brain Research. 1996 Aug;729(1):124–6. doi: 10.1016/0006-8993(96)00407-6.
参考文献:10.1111/j.1476-5381.1996.tb15985.x
摘要:Fernández R, Sabater R, Sáez JA, Montes R, Alba F, Ferrer JMR. Mediation by neurotensin‐receptors of effects of neurotensin on self‐stimulation of the medial prefrontal cortex. British J Pharmacology. 1996 Sep;119(2):299–302. doi: 10.1111/j.1476-5381.1996.tb15985.x.
参考文献:10.1016/s0167-0115(99)00019-1
摘要:Nustede R, Schmidt WE, Horstmann O, Sikovec N, Schemminger R, Becker H. On the effect of xenin and xenin fragments on exocrine pancreas secretion in vivo. Regul Pept. 1999 May 31;81(1-3):61–6. doi: 10.1016/s0167-0115(99)00019-1.
参考文献:10.1016/s0306-4522(99)00016-0
摘要:Zetina ME, Jiménez B, Diaz-Luna F, Mora-Valladares E, Morales MA. Release-depletion and receptor-mediated neuronal internalization of endogenous neurotensin in the stellate ganglion of the cat. Neuroscience. 1999;92(2):655–64. doi: 10.1016/s0306-4522(99)00016-0.
参考文献:10.1007/s00268-002-4055-3
摘要:Evers BM. Endocrine gene neurotensin: molecular mechanisms and a model of intestinal differentiation. World J Surg. 2002 Jul;26(7):799–805. doi: 10.1007/s00268-002-4055-3.
📝 需求与反馈
尽可能描述清楚需求与问题信息
